Alexandria Real Estate Equities, Inc. (ARE) is a publicly traded real estate investment trust (REIT) that focuses on owning, operating, and developing properties for the life sciences, technology, and agtech industries.
The company was founded in 1994 and has expanded over time into several major innovation markets across North America. Its portfolio includes office and laboratory properties in Boston, San Francisco, San Diego, and New York City.
In the life sciences real estate sector, Alexandria has built its reputation on supporting research and development in biotechnology, pharmaceuticals, and other industries. However, recent Real Estate Investment Trusts (REITs) loss claims have brought increased scrutiny to the company.
Alexandria Real Estate Equities (ARE) Investment Misconduct
Questions have emerged in some investor claims involving Alexandria Real Estate Equities based on how the investment was recommended. Investors allege that advisors concentrated too much of their portfolio in ARE without clearly explaining the risks tied to that level of exposure or how a downturn could impact the over all account.
Investment misconduct, such as failing to provide accurate information about the risks associated with volatile or sector-specific investments like ARE, can result in drastic losses for investors.
In light of market fluctuations and challenges specific to ARE, clients have questioned whether they were adequately informed about the potential downsides of investing in Alexandria Real Estate Equities.
Investors who have experienced losses due to overconcentration or unsuitable recommendations involving Alexandria Real Estate Equities may have legal options to recover damages. An investment fraud lawyer can pursue recovery for your losses.
We Have Recovered Over
$350 Million for Our Clients Nationwide.
Complaints and Lawsuits Involving Alexandria Real Estate Equities (ARE)
Recent complaints and lawsuits involving Alexandria Real Estate Equities (ARE) center around concerns over possible investment misconduct due to the company’s performance and financial practices.
In some cases, advisors or investment firms are accused of recommending ARE while downplaying or failing to explain the risks. Investor complaints raise issues such as:
- Unsuitable recommendations: Advisors allegedly placed clients in ARE despite its volatility or without consideration of the investor’s financial goals and risk tolerance.
- Overconcentration: Some investors claim their portfolios were overconcentrated in Alexandria Real Estate Equities or similar REITs, exposing them to unnecessary financial risk.
- Misrepresentation or omissions: Some investors claim that advisors or firms failed to provide complete or accurate information regarding Alexandria’s financial health, market risks, or liquidity challenges.
Current Developments and Stock Price Decline for Alexandria Real Estate Equities (ARE)
Significant stock price declines and other legal actions have raised concerns among ARE investors. These types of companies often adjust their portfolios to address market shifts. However, Alexandria’s recent financial disclosures and impairment charges have drawn scrutiny over how the company managed and communicated its operations and risks.
Alexandria, a REIT specializing in life sciences real estate, announced disappointing third-quarter results for 2025, reporting lower occupancy rates and slower leasing activity than expected.
Additionally, the company disclosed a $323.9 million real estate impairment charge, with $206 million attributed to its Long Island City property in New York. The company described the property as unable to scale as a life sciences destination, contradicting earlier claims about its leasing volume and development pipeline.
ARE’s stock price then plummeted significantly. On October 27, 2025, the stock dropped $14.93 per share (a 19% decline) from $77.87 to $62.94 per share.
Further concerns arose when Alexandria announced a Q4 2025 cash dividend of $0.72 per share, a 45% decrease from the previous quarter. Following this announcement on December 3, 2025, the stock dropped another $5.41 per share, or 10%, to close at $48.42.
Our lawyers are nationwide leaders in investment fraud cases.
How We Can Help You Recover Your Losses
Meyer Wilson Werning helps investors recover losses through REIT claims. We start by reviewing your investment records to determine whether your advisor breached their obligations.
If misconduct is identified, we can file a claim on your behalf through the Financial Industry Regulatory Authority (FINRA) arbitration process, which is commonly required for disputes involving financial advisors.
We Are The firm other lawyers
call for support.
Call Meyer Wilson Werning
Our team works to hold advisors and firms accountable for the financial harm they’ve caused. We’ve recovered over $350 million for our clients, and we work on a contingency fee basis, meaning you pay nothing unless we help recover your losses.
If you’ve experienced significant losses due to ARE investments, contact Meyer Wilson Werning today to learn how we can assist you.
Meyer Wilson Werning can assist only when a financial advisor or broker was involved in placing the client into the scheme. Cases involving standalone social-media scammers are not eligible.
Recovering Losses Caused by Investment Misconduct.